493 related articles for article (PubMed ID: 30273068)
21. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
Tillett W; Egeberg A; Sonkoly E; Gorecki P; Tjärnlund A; Buyze J; Wegner S; McGonagle D
Arthritis Res Ther; 2023 Sep; 25(1):169. PubMed ID: 37715294
[TBL] [Abstract][Full Text] [Related]
22. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
Bissonnette R; Luger T; Thaçi D; Toth D; Lacombe A; Xia S; Mazur R; Patekar M; Charef P; Milutinovic M; Leonardi C; Mrowietz U
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1507-1514. PubMed ID: 29444376
[TBL] [Abstract][Full Text] [Related]
23. A 36-week retrospective open trial comparing the efficacy of biological therapies in nail psoriasis.
Bardazzi F; Antonucci VA; Tengattini V; Odorici G; Balestri R; Patrizi A
J Dtsch Dermatol Ges; 2013 Nov; 11(11):1065-70. PubMed ID: 24119121
[TBL] [Abstract][Full Text] [Related]
24. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study.
Patsatsi A; Kyriakou A; Sotiriadis D
J Dermatolog Treat; 2013 Apr; 24(2):96-100. PubMed ID: 21797806
[TBL] [Abstract][Full Text] [Related]
25. Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis.
Langley RG; Rich P; Menter A; Krueger G; Goldblum O; Dutronc Y; Zhu B; Wei H; Cameron GS; Heffernan MP
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1763-70. PubMed ID: 25693783
[TBL] [Abstract][Full Text] [Related]
26. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
[TBL] [Abstract][Full Text] [Related]
27. Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.
Rich P; Goldblum O; Disch D; Lin CY; Merola JF; Elewski B
J Drugs Dermatol; 2020 Aug; 19(8):741-746. PubMed ID: 32845588
[TBL] [Abstract][Full Text] [Related]
28. Interventions for nail psoriasis.
de Vries AC; Bogaards NA; Hooft L; Velema M; Pasch M; Lebwohl M; Spuls PI
Cochrane Database Syst Rev; 2013 Jan; (1):CD007633. PubMed ID: 23440816
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
[TBL] [Abstract][Full Text] [Related]
30. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
[TBL] [Abstract][Full Text] [Related]
31. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.
Ortonne JP; Paul C; Berardesca E; Marino V; Gallo G; Brault Y; Germain JM
Br J Dermatol; 2013 May; 168(5):1080-7. PubMed ID: 23013207
[TBL] [Abstract][Full Text] [Related]
32. Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study.
Ding Y; Li W; Guan X; Liu N; Zhou Y; Li G; Wang X; Wang Z; Xiao X; Yang B; Lv C; Zhang C; Shi Y
Clin Transl Sci; 2023 Oct; 16(10):1803-1814. PubMed ID: 37644777
[TBL] [Abstract][Full Text] [Related]
33. Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP
Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
[TBL] [Abstract][Full Text] [Related]
34. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
35. Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis.
Reich K; Baraliakos X; Coates LC; Elewski B; Bao W; Kasparek T; Gaillez C; Pournara E; Aassi M; Perella C; Gottlieb AB
Br J Dermatol; 2022 Sep; 187(3):438-441. PubMed ID: 35257363
[TBL] [Abstract][Full Text] [Related]
36. Rapid response of nail psoriasis to secukinumab in patients with moderate to severe psoriasis after 12 weeks of treatment with a total of 24 weeks of follow-up.
Go GM; Hong YJ; Lee HJ; Kim M
Australas J Dermatol; 2024 May; 65(3):e13-e20. PubMed ID: 38288519
[TBL] [Abstract][Full Text] [Related]
37. Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study.
Kyriakou A; Patsatsi A; Sotiriadis D
J Dermatolog Treat; 2013 Jun; 24(3):162-8. PubMed ID: 22136334
[TBL] [Abstract][Full Text] [Related]
38. Treatment of psoriatic nails with indigo naturalis oil extract: a non-controlled pilot study.
Lin YK; See LC; Chang YC; Huang YH; Chen JL; Tsou TC; Leu YL; Shen YM
Dermatology; 2011; 223(3):239-43. PubMed ID: 22056841
[TBL] [Abstract][Full Text] [Related]
39. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
[TBL] [Abstract][Full Text] [Related]
40. Interobserver reliability of the Nail Psoriasis Severity Index.
Aktan S; Ilknur T; Akin C; Ozkan S
Clin Exp Dermatol; 2007 Mar; 32(2):141-4. PubMed ID: 17137477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
